Table 1.
Conditions | Responses | Biological effects | Models used | References |
---|---|---|---|---|
Simultaneous | Priming | Enhanced ceramide | Primary and immortalized mouse macrophages | [14,15,36] |
PA + LPS (in vitro) | Enhanced TNF/IL-6 secretion | |||
JNK dependent | ||||
PA pre-treatment + LPS (in vitro) | Trained immunity | Enhanced TNF/IL-6/IL-1β secretion, all ceramide dependent | Primary mouse macrophages; immortalized human and mouse macrophages | [12,17,35,37] |
Role of mitochondria and MAPK signaling | ||||
PA pre-treatment + LPS (in vivo) | Trained immunity | Enhanced circulating inflammation; decreased survival | Wild-type female BALB/c mice | [12] |
PA pre-treatment + infection (in vivo) | Trained immunity | Enhanced microbial clearance | Rag−/− mice + Candida albicans infection; wild-type female BALB/c mice + Brucella abortus infection | [12,13] |
IL-6, interleukin 6; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; PA, palmitic acid; TNF, tumor necrosis factor.